Company Overview of AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP, a biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription medicines to customers worldwide. It offers a pipeline of medicines primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases. The company was founded in 1912 and is headquartered in Wilmington, Delaware with a strategic research and development center in Gaithersburg, Maryland. It also has research and development, manufacturing, and commercial office locations in California, Delaware, Kentucky, Massachusetts, Maryland, North Carolina, Ohio, and Pennsylvania. AstraZeneca...
1800 Concord Pike
PO Box 15437
Wilmington, DE 19850-5437
Founded in 1912
Key Executives for AstraZeneca Pharmaceuticals LP
Chief Financial Officer and Vice President of Finance - North America
President of Astrazeneca US and Executive Vice President of North America
President of Astrazeneca Canada Inc
Vice President of Medical Affairs and US Head Medical Officer
Vice President of Human Resources
Compensation as of Fiscal Year 2015.
AstraZeneca Pharmaceuticals LP Key Developments
The Third U.S. Circuit Court of Appeals Affirms Dismissal of a Relator's False Claims Act Suit Against Bristol-Meyers Squib Co., E.I. du Pont de Nemours and Co., DuPont Pharmaceuticals Co., AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P
Nov 7 14
The Third U.S. Circuit Court of Appeals affirmed the dismissal of a relator's False Claims Act (FCA) suit against pharmaceutical companies, agreeing with a district court that the relator failed to show he was the original source of information about the companies' alleged wrongdoing. Karl Schumann, proceeding as a qui tam relator under the FCA and corresponding state laws, brought an action against Bristol-Meyers Squib Co., E.I. du Pont de Nemours and Co., DuPont Pharmaceuticals Co., AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P. (collectively, the defendants). Schumann alleged the defendants improperly induced Medco Health Solutions Inc., his employer, to offer certain of the defendants' drugs in its mail-order pharmacies and in health plans it managed; did not include those inducements when calculating the best price for their drugs and thus submitted inaccurate best price reports to the government; overcharged the government based on those inaccurate best prices; and underpaid rebates owed based on those inaccurate best prices. The district court found it lacked subject matter jurisdiction over Schumann's claims because he did not have the requisite direct and independent knowledge to satisfy the original source exception to the FCA's public disclosure bar. As a result, the court dismissed Schumann's claims with prejudice. Schumann appealed. The Third Circuit affirmed the district court's judgment. In so ruling, the Third Circuit found Schumann's knowledge gained through the application of expertise to information publicly disclosed under 31 U.S.C. §3730(e)(4)(A) was not independent, and Schumann failed to aver facts indicating he had direct and independent knowledge of any false or fraudulent claim submitted or caused to be submitted by the defendants. Therefore, Schumann was not an original source of the information underlying his FCA claims against the defendants.
AstraZeneca Pharmaceuticals LP Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 through Sep-24-2014
Sep 10 14
AstraZeneca Pharmaceuticals LP Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 through Sep-24-2014. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Presentation Date & Speakers: Sep-22-2014, Carl Jessop, Due Diligence Director, Christoph Pittius, VP, Head of Transactions, Business Development. Sep-23-2014.
U.S. District Court for the Middle District of Florida Denies a Motion to Dismiss Negligence and Negligent Failure to Warn Claims Against Astrazeneca Pharms. L.P
May 2 14
The U.S. District Court for the Middle District of Florida denied a motion to dismiss negligence and negligent failure to warn claims brought by a drug consumer against AstraZeneca Pharmaceuticals L.P arising from a medical condition the consumer developed after long-term use of a medication produced by the defendant. Sharon King sued AstraZeneca Pharmaceuticals L.P., alleging negligence and negligent failure to warn arising out of injuries allegedly caused by the drugs Prilosec and Nexium, both proton pump inhibitors manufactured by AstraZeneca and used for the treatment of the esophagus. King alleged she used the two medications from 1990 until May 7, 2010, and that in 2005, she began exhibiting symptoms of hypomagnesaemia, a depletion of magnesium, which was not diagnosed until 2009. King alleged that in 2010, she learned of a correlation between hypomagnesaemia and the use of Prilosec and Nexium, and thereupon discontinued her use of the medications. King alleged that AstraZeneca became aware of the correlation between hypomagnesaemia and the use of the two medications in 2006, and at that time, began to publish warnings of the related symptoms in international markets including Scotland and the Netherlands, but did not make similar disclosures in the United States until the Food and Drug Administration revealed them in a drug safety communication on Mar. 2, 2011. AstraZeneca moved to dismiss the complaint. The district court found King provided specific factual allegations in support of her claim that the product warnings provided by AstraZeneca were inadequate. King alleged AstraZeneca knew that Prilosec and Nexium caused hypomagnesaemia as early as 2006, but failed to provide any warnings about the risk. The court found those allegations plausibly suggested the warnings provided by AstraZeneca were inadequate, and the motion to dismiss King's negligence and negligent failure to warn claims was accordingly denied. The court separately rejected AstraZeneca's contention that the complaint was subject to dismissal because King failed to distinguish between the two medications. King adequately alleged AstraZeneca designed, marketed, manufactured and sold the products in question and that both failed to warn of the risk of hypomagnesaemia. The court found that given those allegations, the combining of both medications into a single claim did not warrant dismissal.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|